Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of HAPLN1-PTR1 on RPMI8226 multiple myeloma cells

ABSTRACT: Effect of HAPLN1-PTR1 on RPMI8226 multiple myeloma cells

PROVIDER: PRJNA836926 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR19159226.fastq.gz	Fastqsanger.gz
	SRR19159227.fastq.gz	Fastqsanger.gz
	SRR19159228.fastq.gz	Fastqsanger.gz
	SRR19159229.fastq.gz	Fastqsanger.gz
	SRR19159230.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Effect of HAPLN1-PTR1 on RPMI8226 multiple myeloma cells

Project description:To investigate the role of HAPLN1 in multiple myeloma, we treated RPMI8226 multiple myeloma cells with recombinant HAPLN1-PTR1. We then performed gene expression profiling analysis using data obtained from RNA-seq.

2022-09-06 | GSE202672 | GEO

Effect of HAPLN1-PTR1 on STAT1 knockout RPMI8226 multiple myeloma cells

Project description:To identify the HAPLN1-induced genes regulated by STAT1 in multiple myeloma, we treated RPMI8226 multiple myeloma cells (WT or STAT1 KO) with recominant HAPLN1-PTR1. We then performed gene expression profiling analysis using data obtained from RNA-seq.

2023-12-06 | GSE237216 | GEO

Effect of HAPLN1-PTR1 on STAT1 knockout RPMI8226 multiple myeloma cells

Project description:Effect of HAPLN1-PTR1 on STAT1 knockout RPMI8226 multiple myeloma cells

| PRJNA994179 | ENA

Drug resistance-related changes in gene expression profile in multiple myeloma

Project description:1) We identified the genes whose expression was up- and down-regulated by the adhesion to bone marrow stromal cells in human multiple myeloma cell line RPMI8226. 2) We identified the genes whose expression was up- and down-regulated by the PI3K inhibitor PF-04691502 in human multiple myeloma cell line RPMI8226. We isolated mRNA from the multiple myeloma cell line RPMI8226 under drug-resistant conditions, and subjected them to gene expression profiling using an Agilent GeneChip Array.

2015-03-04 | E-GEOD-66466 | biostudies-arrayexpress

DNA methylation data from cell lines originating from patients with multiple myeloma

Project description:We performed genome-wide DNA methylation profiling of KMS11, MM.1S, and RPMI8226 multiple myeloma cell lines to identify methylation changes distinct to each cell line Three multiple myeloma cell lines (KMS11, MM.1S, and RPMI8226) with two replicates each

2015-06-30 | E-GEOD-68259 | biostudies-arrayexpress

Drug resistance-related changes in gene expression profile in multiple myeloma

2015-03-04 | GSE66466 | GEO

Illumina Infinium whole-genome SNP-CN data from cell lines originating from patients with multiple myeloma

Project description:We performed Illumina Infinium whole-genome SNP-CN profiling of KMS11, MM.1S, and RPMI8226 multiple myeloma cell lines to detect gene copy number variants distinct to each cell line Three multiple myeloma cell lines (KMS11, MM.1S, and RPMI8226)

2015-06-30 | E-GEOD-68258 | biostudies-arrayexpress

Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells

Project description:Multiple myeloma RPMI8226 cells adapted to growth in melphalan display a shift towards Warburg metabolism and modulated oxidative stress signaling. Inhibitors targeting specific enzymes in these pathways are selectively toxic to the melphalan-resistant cells. To investigate large scale alterations in gene expression accompanying melphalan resistance, we used the multiple myeloma cell line RPMI8226 and its melphalan-resistant derivative LR5. The stable isotope labeling by amino acids in cell culture (SILAC) approach.

2015-05-26 | PXD001276 | Pride

Effect of c-MET inhibitor SU11274 upon sensitive (RPMI8226) or multi-resistant (RPMI8226/R5) Multiple Myeloma cell lines

Project description:The c-MET signaling axis is increasingly implicated in tumorigenesis and chemioresistance. In this study, we investigated gene expression modifications induced by SU11274 (Selleck Chemicals, Boston, USA), a novel selective c-MET inhibitor, in a pair of isogenic multiple myeloma (MM) cell lines either sensitive (RPMI8226) or multi-resistant, highly c-MET expressing (RPMI8226/R5) cells. On the whole, RPMI8226/R5 cells after SU11274 were characterised by wider and diverse gene expression modifications than RPMI8226, indicating that c-MET over-expression, and its inhibition, is an important aspect of the adaptive response associated to drug resistance.

2012-05-25 | GSE38204 | GEO

Multiple Myeloma cells

Project description:Multiple Myeloma cells

| PRJNA800411 | ENA